Mineralys Therapeutics Inc (MLYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Fiscal Year End Date: 12/31
(Values in U.S. thousands)
| 12-2025 | 09-2025 | 06-2025 | 03-2025 | 12-2024 | |
| Assets | |||||
| Current Assets | |||||
| Cash & Cash Equivalents | 172,921 | 217,597 | 101,788 | 165,007 | 114,091 |
| Marketable Securities | 483,714 | 376,031 | 223,128 | 178,019 | 84,096 |
| TOTAL | $661,386 | $599,796 | $335,269 | $354,506 | $205,351 |
| Non-Current Assets | |||||
| PPE Net | 38 | 7 | 22 | 38 | 53 |
| Other Non-Current Assets | 382 | 144 | 433 | 397 | 499 |
| TOTAL | $420 | $151 | $455 | $435 | $552 |
| Total Assets | $661,806 | $599,947 | $335,724 | $354,941 | $205,903 |
| Liabilities | |||||
| Current Liabilities | |||||
| Accounts payable and accrued liabilities | 2,017 | 1,121 | 3,164 | 373 | 479 |
| Accrued Expenses | 13,096 | 22,399 | 19,009 | 13,013 | 14,167 |
| TOTAL | $15,113 | $23,520 | $22,173 | $13,386 | $14,646 |
| Non-Current Liabilities | |||||
| TOTAL | $N/A | $N/A | $N/A | $N/A | $N/A |
| Total Liabilities | $15,113 | $23,520 | $22,173 | $13,386 | $14,646 |
| Shareholders' Equity | |||||
| Shares Outstanding, K | 82,399 | 79,140 | 66,295 | 65,175 | 49,836 |
| Common Shares | 8 | 8 | 6 | 6 | 5 |
| Retained earnings | -457,169 | -424,935 | -388,003 | -344,729 | -302,518 |
| TOTAL | $646,693 | $576,427 | $313,551 | $341,555 | $191,257 |
| Total Liabilities And Equity | $661,806 | $599,947 | $335,724 | $354,941 | $205,903 |